Published in Am J Trop Med Hyg on September 01, 2006
Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial. BMJ (2008) 2.66
World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria. Malar J (2007) 2.30
A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa. N Engl J Med (2014) 1.36
Safety and efficacy of co-trimoxazole for treatment and prevention of Plasmodium falciparum malaria: a systematic review. PLoS One (2013) 1.29
Genetic structure of Plasmodium falciparum populations between lowland and highland sites and antimalarial drug resistance in Western Kenya. Infect Genet Evol (2009) 1.14
In vitro activity of antifolate and polymorphism in dihydrofolate reductase of Plasmodium falciparum isolates from the Kenyan coast: emergence of parasites with Ile-164-Leu mutation. Antimicrob Agents Chemother (2009) 1.04
HIV treatments have malaria gametocyte killing and transmission blocking activity. J Infect Dis (2013) 0.99
Prescription patterns and drug use among pregnant women with febrile Illnesses in Uganda: a survey in out-patient clinics. BMC Infect Dis (2013) 0.95
Plasmodium falciparum dihydrofolate reductase and dihyropteroate synthase mutations and the use of trimethoprim-sulfamethoxazole prophylaxis among persons infected with human immunodeficiency virus. Am J Trop Med Hyg (2010) 0.91
Malaria prevention reduces in-hospital mortality among severely ill tuberculosis patients: a three-step intervention in Bissau, Guinea-Bissau. BMC Infect Dis (2011) 0.89
Cotrimoxazole prophylactic treatment prevents malaria in children in sub-Saharan Africa: systematic review and meta-analysis. Trop Med Int Health (2014) 0.89
A cross-sectional study of sub-clinical Plasmodium falciparum infection in HIV-1 infected and uninfected populations in Mozambique, South-Eastern Africa. Malar J (2012) 0.87
Monitoring antifolate resistance in intermittent preventive therapy for malaria. Trends Parasitol (2013) 0.86
Prevalence of Plasmodium falciparum resistance markers to sulfadoxine-pyrimethamine among pregnant women receiving intermittent preventive treatment for malaria in Uganda. Antimicrob Agents Chemother (2015) 0.86
Antibiotics in malaria therapy: which antibiotics except tetracyclines and macrolides may be used against malaria? Malar J (2016) 0.76
Impact of cotrimoxazole and insecticide-treated nets for malaria prevention on key outcomes among HIV-infected adults in low- and middle-income countries: a systematic review. J Acquir Immune Defic Syndr (2015) 0.75
Effect of co-trimoxazole on mortality in HIV-exposed but uninfected children in Botswana (the Mpepu Study): a double-blind, randomised, placebo-controlled trial. Lancet Glob Health (2017) 0.75
Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med (2003) 15.48
Estimated HIV incidence in the United States, 2006-2009. PLoS One (2011) 13.03
Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS (2006) 9.45
Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis (2010) 8.37
Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med (2006) 7.68
Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis (2007) 6.45
Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog (2008) 6.07
Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol (2004) 5.86
Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet (2002) 5.80
Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet (2006) 5.56
Chemical genetics of Plasmodium falciparum. Nature (2010) 5.52
Differences in human immunodeficiency virus care and treatment among subpopulations in the United States. JAMA Intern Med (2013) 5.39
The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004. Clin Infect Dis (2007) 5.36
Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda. Lancet (2006) 5.34
Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA (2005) 5.29
Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis (2008) 4.91
A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neonates. N Engl J Med (2002) 4.88
Risk factors for recent HIV infection in Uganda. JAMA (2008) 4.84
Effect of reduction in household air pollution on childhood pneumonia in Guatemala (RESPIRE): a randomised controlled trial. Lancet (2011) 4.79
Health care-associated invasive MRSA infections, 2005-2008. JAMA (2010) 4.79
Mortality in HIV-infected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort study. Lancet (2008) 4.70
Rapid diagnostic tests for malaria at sites of varying transmission intensity in Uganda. J Infect Dis (2008) 4.60
Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS Pathog (2009) 4.56
Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS (2007) 4.52
The costs and effectiveness of four HIV counseling and testing strategies in Uganda. AIDS (2009) 4.45
Diagnostic accuracy of nucleic acid amplification tests for tuberculous meningitis: a systematic review and meta-analysis. Lancet Infect Dis (2003) 4.41
Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med (2009) 4.38
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial. Lancet (2009) 4.33
In vivo parasitological measures of artemisinin susceptibility. J Infect Dis (2010) 4.25
Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet (2004) 4.19
Epidemiology of invasive group a streptococcus disease in the United States, 1995-1999. Clin Infect Dis (2002) 4.08
Treatment of malaria restricted to laboratory-confirmed cases: a prospective cohort study in Ugandan children. Malar J (2007) 4.05
Population-based hematologic and immunologic reference values for a healthy Ugandan population. Clin Diagn Lab Immunol (2004) 3.92
Antimalarial drug discovery: efficacy models for compound screening. Nat Rev Drug Discov (2004) 3.90
Transmission of human herpesvirus 8 by blood transfusion. N Engl J Med (2006) 3.80
Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial. Lancet (2002) 3.78
Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp. Am J Trop Med Hyg (2003) 3.71
Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health (2007) 3.69
Reproductive intentions and outcomes among women on antiretroviral therapy in rural Uganda: a prospective cohort study. PLoS One (2009) 3.66
Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. JAMA (2007) 3.62
Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis (2010) 3.61
Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. Nat Med (2003) 3.54
HIV transmission risk behavior among HIV-infected adults in Uganda: results of a nationally representative survey. AIDS (2008) 3.52
Unfinished business--expanding HIV testing in developing countries. N Engl J Med (2006) 3.48
Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settings. J Acquir Immune Defic Syndr (2006) 3.38
Home management of malaria with artemether-lumefantrine compared with standard care in urban Ugandan children: a randomised controlled trial. Lancet (2009) 3.21
Disclosure of HIV status and adherence to daily drug regimens among HIV-infected children in Uganda. AIDS Behav (2006) 3.18
Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial. Lancet (2004) 3.12
Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections. JAMA (2004) 3.05
Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. Lancet (2007) 2.99
Bacterial meningitis in the United States, 1998-2007. N Engl J Med (2011) 2.99
Artemisinin activity against Plasmodium falciparum requires hemoglobin uptake and digestion. Proc Natl Acad Sci U S A (2011) 2.94
Effectiveness of quinine versus artemether-lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: randomised trial. BMJ (2009) 2.84
Comparison of home and clinic-based HIV testing among household members of persons taking antiretroviral therapy in Uganda: results from a randomized trial. J Acquir Immune Defic Syndr (2010) 2.83
Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS One (2008) 2.78
Processes and outcomes of HIV serostatus disclosure to sexual partners among people living with HIV in Uganda. AIDS Behav (2007) 2.78
Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic. Antimicrob Agents Chemother (2006) 2.74
Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda. PLoS Clin Trials (2006) 2.72
Short report: proximity to mosquito breeding sites as a risk factor for clinical malaria episodes in an urban cohort of Ugandan children. Am J Trop Med Hyg (2003) 2.68
Routine intrapartum HIV counseling and testing for prevention of mother-to-child transmission of HIV in a rural Ugandan hospital. J Acquir Immune Defic Syndr (2006) 2.67
Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. PLoS Clin Trials (2007) 2.63
Desire for children and pregnancy risk behavior among HIV-infected men and women in Uganda. AIDS Behav (2006) 2.59
Home-based model for HIV voluntary counselling and testing. Lancet (2003) 2.57
Synthesis and evaluation of isatins and thiosemicarbazone derivatives against cruzain, falcipain-2 and rhodesain. Bioorg Med Chem Lett (2003) 2.54
Population-based study of invasive disease due to beta-hemolytic streptococci of groups other than A and B. Clin Infect Dis (2009) 2.53
Effect of HIV-1 infection on antimalarial treatment outcomes in Uganda: a population-based study. J Infect Dis (2005) 2.51
HIV prevention for a threatened continent: implementing positive prevention in Africa. JAMA (2006) 2.51
Cotrimoxazole prophylaxis by HIV-infected persons in Uganda reduces morbidity and mortality among HIV-uninfected family members. AIDS (2005) 2.50
Antiretroviral therapy improves renal function among HIV-infected Ugandans. Kidney Int (2008) 2.49
Toward understanding the risk of secondary airborne infection: emission of respirable pathogens. J Occup Environ Hyg (2005) 2.48
Malaria in Uganda: challenges to control on the long road to elimination: I. Epidemiology and current control efforts. Acta Trop (2011) 2.46
Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. Clin Infect Dis (2007) 2.44